Ameriprise
GMAB icon

Ameriprise’s Genmab GMAB Stock Holding History

Ameriprise’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
61,924
+434
+0.7% +$13K ﹤0.01% 3040
2025
Q4 		$1.89M Buy
61,490
+2,314
+4% +$72.1K ﹤0.01% 3029
2025
Q3 		$1.81M Buy
59,176
+2,462
+4% +$60K ﹤0.01% 3054
2025
Q2 		$1.17M Buy
+56,714
New +$1.16M ﹤0.01% 3194
2024
Q2 		– Sell
-6,996
Closed -$209K – 3898
2024
Q1 		$209K Buy
+6,996
New +$206K ﹤0.01% 3679
2023
Q4 		– Sell
-6,268
Closed -$221K – 3924
2023
Q3 		$221K Buy
6,268
+337
+6% +$12.8K ﹤0.01% 3675
2023
Q2 		$225K Buy
5,931
+601
+11% +$24K ﹤0.01% 3698
2023
Q1 		$201K Sell
5,330
-228
-4% -$8.76K ﹤0.01% 3728
2022
Q4 		$236K Buy
+5,558
New +$229K ﹤0.01% 3667
2022
Q2 		– Sell
-5,669
Closed -$205K – 3932
2022
Q1 		$205K Sell
5,669
-6,812
-55% -$234K ﹤0.01% 3753
2021
Q4 		$494K Buy
12,481
+6,623
+113% +$276K ﹤0.01% 3530
2021
Q3 		$255K Buy
5,858
+232
+4% +$10.4K ﹤0.01% 3637
2021
Q2 		$230K Sell
5,626
-1,417
-20% -$54.7K ﹤0.01% 3720
2021
Q1 		$232K Sell
7,043
-29,324
-81% -$1.1M ﹤0.01% 3672
2020
Q4 		$1.48M Buy
36,367
+2,810
+8% +$105K ﹤0.01% 2916
2020
Q3 		$1.23M Buy
33,557
+27,559
+459% +$996K ﹤0.01% 2882
2020
Q2 		$204K Sell
5,998
-36,071
-86% -$983K ﹤0.01% 3490
2020
Q1 		$891K Buy
42,069
+796
+2% +$17.7K ﹤0.01% 2871
2019
Q4 		$921K Buy
41,273
+421
+1% +$9.19K ﹤0.01% 3090
2019
Q3 		$827K Buy
+40,852
New +$805K ﹤0.01% 3097

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ameriprise's GMAB Position: Q1 2026 in Review

Ameriprise increased its Genmab (GMAB) stake by 0.71% in Q1 2026, buying an estimated $13K and bringing the position to 61,924 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Ameriprise first reported a position in GMAB in Q3 2019 and has held it in 20 quarters since. The position peaked at $1.89M in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Ameriprise held 61,924 shares of Genmab worth $1.66M as of Q1 2026.
  • Ameriprise bought 434 Genmab shares in Q1 2026, an estimated $13K.
  • Genmab made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3040 holding.
  • Ameriprise first reported a position in Genmab in Q3 2019 and has held it in 20 quarters since.
  • Ameriprise's Genmab position peaked at $1.89M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.